What You Should Know:

你应该知道的：

–

–

PhaseV

第五阶段

, a company at the forefront of applying

，一家处于应用前沿的公司

artificial intelligence (AI)

人工智能（AI）

and machine learning (ML) to clinical development raies $50M in Series A funding round co-led by

以及机器学习（ML）应用于临床开发，在A轮融资轮次中筹集了5000万美元，由以下机构共同领投：

Accel

加速器

and

和

Insight Partners

洞察合伙人

, with participation from existing investors

，现有投资者参与其中

Viola Ventures

维奥拉风险投资公司

,

，

EXOR

异或

, and

，以及

LionBird

狮子鸟

. This round brings PhaseV’s total funding to date to $65M.

此轮融资使 PhaseV 的总融资额达到 6500 万美元。

– The new capital is earmarked to fuel PhaseV’s mission to support pharmaceutical companies, biotech firms, and contract research organizations (CROs) in leveraging AI and ML to enhance the efficiency and success rates of clinical trials.

– 新资金将用于推动 PhaseV 的使命，即支持制药公司、生物技术公司和合同研究组织 (CRO) 利用人工智能和机器学习提高临床试验的效率和成功率。

Addressing a “Critical Crossroads” in Clinical Development

针对临床开发中的“关键十字路口”

The pharmaceutical industry faces mounting pressure to accelerate drug development, reduce substantial costs, and improve the historically low success rates of clinical trials. Traditional methodologies are increasingly struggling to meet these evolving demands.

制药行业面临着加快药物研发、降低巨额成本以及提高历史上较低的临床试验成功率的压力。传统方法越来越难以满足这些不断变化的需求。

“The pharma industry is at a critical crossroads, as traditional approaches to designing and executing clinical trials struggle to meet growing demands for speed, cost-efficiency, and higher success rates,” said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV. “This funding fuels our mission to support more pharma, biotech, and CROs in embracing AI and machine learning to unlock the next era of clinical development.

“制药行业正处于一个关键的十字路口，因为设计和执行临床试验的传统方法难以满足对速度、成本效益和更高成功率日益增长的需求，”PhaseV首席执行官兼联合创始人Raviv Pryluk博士说道。“这笔资金将推动我们的使命，支持更多制药、生物技术和合同研究组织（CRO）采用人工智能和机器学习，开启临床开发的新时代。”

Our solutions deliver clear ROI by increasing trial success rates, reducing costs, and accelerating time to market.”.

我们的解决方案通过提高试验成功率、降低成本并加快上市时间，带来了明确的投资回报率。"

PhaseV’s AI Platform: A Holistic Solution for Modern Trials

PhaseV的人工智能平台：现代试验的全面解决方案

PhaseV is developing a vertical AI platform designed to provide comprehensive solutions across the entire clinical development lifecycle, from initial design through to execution. The platform has already seen rapid market adoption, with over 30 global pharmaceutical companies utilizing its AI/ML capabilities across more than 20 therapeutic areas, including neurology, oncology, GI disorders, immunology, metabolic diseases, and rare diseases..

PhaseV 正在开发一个垂直的人工智能平台，旨在为整个临床开发生命周期提供全面的解决方案，从初始设计到执行阶段。该平台已经迅速获得市场认可，已有超过 30 家全球制药公司利用其人工智能/机器学习功能，涵盖神经学、肿瘤学、胃肠病、免疫学、代谢疾病和罕见病等 20 多个治疗领域。

Augmented by a robust data lake that integrates high-quality patient-level data, clinical trial results, real-world evidence, and peer-reviewed insights, PhaseV’s platform currently comprises four core applications:

通过一个强大的数据湖来增强，该数据湖整合了高质量的患者层面数据、临床试验结果、真实世界证据和经过同行评议的见解，PhaseV 的平台目前包含四个核心应用：

Trial Optimizer:

试验优化器：

For designing and implementing more efficient Bayesian, adaptive, and fixed clinical trials.

为了设计和实施更高效的贝叶斯、适应性和固定临床试验。

Causal ML:

因果机器学习：

Employing heterogeneous treatment effect estimation to uncover hidden signals in clinical data, identifying patient subpopulations and endpoints with the highest potential for success.

利用异质性处理效应估计来揭示临床数据中的隐藏信号，识别具有最高成功潜力的患者亚群和终点。

Causal Disease Modeling:

因果疾病建模：

To inform new research and development strategies and support life cycle management for therapies.

为治疗策略提供信息以支持新研发战略和生命周期管理。

Clinical Operations:

临床操作：

Utilizing Causal ML for data-driven site selection, analyzing site performance, real-time trial progress monitoring, and integrating virtual control arms.

利用因果机器学习进行数据驱动的站点选择、分析站点性能、实时试验进度监控以及整合虚拟对照组。

Demonstrated Impact: Boosting Efficiency and Success Rates

证明的影响：提高效率和成功率

PhaseV reports that its platform has demonstrated significant improvements for its clients, including a potential reduction in trial costs by 50%, a decrease in patient enrollment size and trial duration by 40%, and a more than 30% increase in the likelihood of trial success. In a recent notable case, PhaseV assisted a leading global pharmaceutical company in shortening its time-to-market by an impressive 15 months..

PhaseV报告称，其平台已为客户提供显著改进，包括试验成本潜在降低50%，患者招募规模和试验时长减少40%，以及试验成功可能性提升30%以上。在最近一个知名案例中，PhaseV协助一家全球领先的制药公司将其上市时间缩短了惊人的15个月。